

TABLE 1.—SUBSTANCES RECOMMENDED FOR TESTING—Continued

| Substance [CAS Number] | Nominated by | ICCEC recommendations | Study rationale; other information |
|-------------------------------------|------------------------------------|---|--|
| S-Adenosylmethionine, [29908-03-0]. | National Cancer Institute | — <i>In vitro</i> genotoxicity testing (Syrian hamster embryo cell transformation and DNA alkylation assays). —Subchronic toxicity testing dependent on results of genotoxicity studies. | Widespread exogenous human exposure through use as a dietary supplement; limited toxicity data available. |
| Senna [8013-11-4] | Food and Drug Administration | —Carcinogenicity testing in p53 transgenic mouse model | Data needed to complete safety evaluation of stimulant laxatives; transgenic studies will complement manufacturer sponsored carcinogenicity studies. |

TABLE 2.—SUBSTANCES FOR WHICH A TESTING RECOMMENDATION IS DEFERRED PENDING RECEIPT AND CONSIDERATION OF ADDITIONAL INFORMATION

| Substance [CAS Number] | Nominated by | Nominated for | Nomination rationale | Additional information needed |
|--|---|---|--|---|
| 1,3-Dichloropropane, [142-28-9], 2,2-Dichloropropane, [594-20-7], 1,1-Dichloropropene, [563-58-6]. | Environmental Protection Agency; National Institute of Environmental Health Sciences. | —Short-term comprehensive drinking water toxicity studies. —Pharmacokinetics —Medaka studies —Testing in human bladder cell transformation model. | Drinking water contaminants with high health research priority; very limited toxicity data; known toxicity and carcinogenicity of structurally similar compounds. | Additional drinking water occurrence data; production volumes; potential sources of drinking water contamination; anticipated regulatory value of additional toxicity data. |
| Hydergine, [8067-24-1]. | National Cancer Institute. | —Genotoxicity testing. | Ergot alkaloid prescription drug with recent increase in "off label" and dietary supplement use in healthy individuals; lack of available information on toxicity and carcinogenicity. | Dietary supplement sales and use information; regulatory agency information needs. |
| Yohimbe bark extract, [85117-22-2], Yohimbine, [146-48-5]. | National Cancer Institute. | —Micronucleus assay. | Significant human exposure through use as a dietary supplement; suspicion of carcinogenicity of yohimbine based on structural similarity to reserpine. | Dietary supplement use levels and patterns; regulatory agency information needs. |

[FR Doc. 00-30715 Filed 12-1-00; 8:45 am]
BILLING CODE 4140-00-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Substance Abuse and Mental Health Services Administration

Agency Information Collection Activities: Submission for OMB Review; Comment Request

Periodically, the Substance Abuse and Mental Health Services Administration (SAMHSA) will publish a list of information collection requests under OMB review, in compliance with the Paperwork Reduction Act (44 U.S.C. Chapter 35). To request a copy of these documents, call the SAMHSA Reports Clearance Officer on (301) 443-7978.

Treatment Improvement Protocols (TIPs) Evaluation Project—Prospective Study—New—Since 1993, SAMHSA's

Center for Substance Abuse Treatment has published 37 Treatment Improvement Protocols, which provide administrative and clinical practice guidance to the substance abuse treatment field. This is the third of three major studies and is designed to assess readers' use of TIPs and the impact of TIPs on changing substance abuse treatment practices.

The Prospective Study seeks to determine the most cost effective level of support needed by substance abuse treatment providers to implement in practice the information contained in TIPs. Specifically, this study will examine the use of TIP # 35, "Enhancing Motivation for Change in Substance Abuse Treatment," by treatment professionals in four different areas of the country. The study will use a pretest/post-test experimental design in which treatment facilities will be randomly assigned to one of four conditions: (1) The control group

(which will receive the TIP and no additional support); (2) a TIP-plus curriculum group; (3) a TIP-plus curriculum and training group; and (4) a TIP-plus curriculum, training, and ongoing support group.

Data will be collected at baseline and follow-up. Measures will include providers' awareness of TIP 35, their knowledge of the content contained in this TIP, their attitudes toward the TIP and its content, and their use of this TIP and its impact on practices within their facilities. Burden for State substance abuse (SSA) agency directors in the four areas of the country chosen will consist of information gathering by telephone. Burden for other respondents will consist of completing the pretest and post-test questionnaires. The total estimated burden for this project, to be completed in a 1-year period, is summarized below.

| Respondent | Number of respondents | Responses/ respondent | Average burden/response (hrs.) | Total burden (hrs.) |
|----------------------------|-----------------------|-----------------------|--------------------------------|---------------------|
| SSA Directors | 6 | 1 | 1.0 | 6 |
| Pretest: | | | | |
| Facility Directors | 577 | 1 | .14 | 81 |
| Clinical Supervisors | 577 | 1 | .14 | 81 |
| Program Counselors | 2,350 | 1 | .14 | 329 |
| Post-test: | | | | |
| Facility Directors | 577 | 1 | .19 | 110 |
| Clinical Supervisors | 577 | 1 | .19 | 110 |
| Program Counselors | 2,350 | 1 | .19 | 447 |
| Total | 3,510 | | | 1,164 |

Written comments and recommendations concerning the proposed information collection should be sent within 30 days of this notice to: Stuart Shapiro, Human Resources and Housing Branch, Office of Management and Budget, New Executive Office Building, Room 10235, Washington, DC 20503.

Dated: November 27, 2000.

Richard Kopanda,

Executive Officer, SAMHSA.

[FR Doc. 00-30757 Filed 12-1-00; 8:45 am]

BILLING CODE 4162-20-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Substance Abuse and Mental Health Services Administration

Center for Substance Abuse Prevention; Notice of Meeting

Pursuant to Public Law 92-463, notice is hereby given of the meeting of the Center for Substance Abuse Prevention (CSAP) Drug Testing Advisory Board to be held in December 2000. A portion of the meeting will be open and will include a Department of Health and Human Services drug testing program update, a Department of Transportation drug testing program update, and an update on the draft guidelines for alternative specimen testing and on-site testing.

If anyone needs special accommodations for persons with disabilities, please notify the Contact listed below.

The meeting will also include the review, discussion, and evaluation of sensitive National Laboratory Certification Program (NLCP) internal operating procedures and program development issues. Therefore, a portion of the meeting will be closed to the public as determined by the SAMHSA Administrator in accordance with Title 5 U.S.C. 552b(c)(2), (4), and (6) and 5 U.S.C. App. 2, section 10(d).

A roster of the board members may be obtained from: Mrs. Giselle Hersh, Division of Workplace Programs, 5600 Fishers Lane, Rockwall II, Suite 815, Rockville, MD 20857, Telephone: (301) 443-6014. The transcript for the open session will be available on the following website: www.health.org/workplace. Additional information for this meeting may be obtained by contacting the individual listed below.

Committee Name: Center for Substance Abuse Prevention Drug Testing Advisory Board.

Meeting Date: December 5, 2000; 8:30 a.m.-4:30 p.m.; December 6, 2000; 8:30 a.m.-3:30 p.m.

Place: Embassy Suites Hotel, 4300 Military Road, Chevy Chase, Maryland 20815.

Type: Open: December 5, 2000; 8:30 a.m.-Noon; Closed: December 5, 2000; Noon-4:30 p.m.; Closed: December 6, 2000; 8:30 a.m.-3:30 p.m.

Contact: Donna M. Bush, Ph.D., Executive Secretary, Telephone: (301) 443-6014, and FAX: (301) 443-3031.

This notice is being published less than 15 days prior to the meeting due to the urgent need to meet timing limitations imposed by the review and funding cycle.

Dated: November 27, 2000.

Toian Vaughn,

Committee Management Officer, Substance Abuse and Mental Health Services Administration.

[FR Doc. 00-30699 Filed 12-1-00; 8:45 am]

BILLING CODE 4162-20-U

DEPARTMENT OF THE INTERIOR

Fish and Wildlife Service

Extension of Comment Period: Draft Policy on Maintaining the Ecological Integrity of the National Wildlife Refuge System

AGENCY: Fish and Wildlife Service, Interior.

ACTION: Notice, extension of comment period.

SUMMARY: We are extending the comment period on the **Federal Register**

notice dated October 17, 2000 (65 FR 61356) that invites the public to comment on our draft ecological integrity policy.

DATES: Submit comments on or before December 15, 2000.

ADDRESSES: Send comments concerning this draft ecological integrity policy via mail, fax or email to: Elizabeth Souheaver, Chief, Branch of Wildlife Resources, National Wildlife Refuge System, U.S. Fish and Wildlife Service, 4401 North Fairfax Drive, Room 670, Arlington, Virginia 22203; fax (703) 358-2248; email: ecointegrity_policy_comments@fws.gov.

FOR FURTHER INFORMATION CONTACT: Elizabeth Souheaver, Chief, Branch of Wildlife Resources, (703) 358-1744.

SUPPLEMENTARY INFORMATION: In a **Federal Register** notice dated October 17, 2000, we published our draft ecological integrity policy. We propose to establish an internal policy to guide personnel of the National Wildlife Refuge System (System) in implementing the clause of the National Wildlife Refuge System Improvement Act of 1997 that calls for maintaining the "biological integrity, diversity, and environmental health" of the System. The holistic integration of these three qualities constitutes ecological integrity.

We received several requests to extend the public comment period beyond the December 1, 2000 due date. In order to ensure that the public has an adequate opportunity to review and comment on our draft policy, we are extending the comment period to December 15, 2000.

Dated: November 29, 2000.

Jamie Rappaport Clark,

Director, U.S. Fish and Wildlife Service.

[FR Doc. 00-30781 Filed 12-1-00; 8:45 am]

BILLING CODE 4310-55-P